HITV Lab

Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

Home HITV Cancer Therapy How HITV Works HITV Treatment Protocol

Thursday29 June 2017

HITV Treatment Protocol

Scientific Basis of Dr Kenichiro Hasumi's HITV Treatment Protocol

Scientific basis of Dr Hasumi HITV Protocol
The diagram above outlines the new strategies being pursued to treat cancer, viz :
Strategy 1

Remove the tumor's mask
Cancer cells hide within normal structures like blood vessels. In order to conceal themselves, cancer cells rely on proteins from nearby healthy cells to hide their malignant proteins. New agents such as engineered peptide antibodies are increasingly able to strip away these disguises, exposing the tumors.

Strategy 2 

Make the tumor less productive
Cancer cells actively pump out factors called immune system suppressors that wave off immune sentries and mislead them into thinking that the tumors are normal, healthy cells. New compounds currently being tested can suppress the suppressors. Cancers are also rich in suppressor T cells that direct the natural killer cells not to attack the cancer cells resulting in immune tolerance. Certain drugs and radiation can wipe out these suppressor T cells and break the immune tolerance.

Strategy 3 

Stack the immune system's deck
The body's T cells, which target invaders, may not be able to recognize the cancer cells.  However, it is now possible to take from a patient some mononuclear cells and induce them to differentiate into immature dendritic cells (or antigen presenting cells).  When mixed with cancer cells, the dendritic cells will identify the cancer cell proteins and pass the information to cytotoxic T lymphocytes (natural killer T cells), thereby training the infantry T cells to spot the bad guys. The killer T cell population can also be enhanced in the lab and then injected back into the body.

Strategy 4 

Build the right immune cells
Another way to sensitize T cells to detect cancer cells is to redesign them for the job. Scientist does this by extracting the cells, genetically modifying them to recognize telltale cancer proteins and then using these supercells to treat the patient.

Dr Kenichiro Hasumi's HITV protocol is Strategies 2 and 3 in combination with conventional radiotherapy. This patient specific induced therapeutic cancer vaccine is believed to be effective in killing off microscopic and tiny nests of cancer cells, thereby preventing any future cancer recurrence.

 

Firstly, the intra-tumoral injection of immature dendritic cells  followed by infusion of cytokine activated memory T cells results in induction of millions of cytotoxic T cells which have been trained to zero in on the cancer cells.

 

This is followed by radiotherapy a week later which causes DNA damage, protein damage and apoptosis of the cancer cells resulting in debulking of the tumour and release of tumour antigens. Radiotherapy also wipes out the regulatory T cells, thereby helping to break up the cancer's immune tolerance.

 

A second intra-tumoral injection of immature dendritic cells followed by activated memory T cells infusion allows the immune system to boost the induction of more cytotoxic T lymphocytes which will mop up all remaining cancer cells including those which could have undergone transformation or mutation. This patient specific induced therapeutic cancer vaccine is believed to be effective in killing off microscopic and tiny nests of cancer cells, thereby preventing any future cancer recurrence.

 

Radiographic Evidence of Patient Response to Treatment :

Radiographic Evidence HITV Efficacy A Radiographic Evidence HITV Efficacy B
Radiographic Evidence HITV Efficacy C

Figures A to C

Computed tomography ( CT ) radiographs showing metastatic cancer sites ( solid arrows ) before and after treatment in two breast cancer and one gastric cancer patient, respectively.

Radiographic Evidence HITV Efficacy D

Figure D

PET-CT showing resolution of treated ( circled ) and un-treated metastatic sites ( open arrows ) in a patient with cervical cancer.

Circled sites were injected with immature dendritic cells ( iDC ) followed by intensity modulated radiotherapy ( IMRT ) as per protocol and resolved as were untreated metastatic lesions ( open arrows ).

[ Source : Figure 2, Page 11 “Therapeutic Response in Patients with Advanced Malignancies Treated with Combined Dendritic Cell–Activated T Cell Based Immunotherapy and Intensity–Modulated Radiotherapy by Kenichiro Hasumi 1, Yukimasa Aoki 1, Ryuko Watanabe 1, Kim G. Hankey 2 and Dean L. Mann”. Cancers 2011, 3, 2223-2242; doi : 10.3390/cancers3022223 ]

 

Ideal conditions for HITV Therapy :

HITV therapy has been found to be highly effective in the following patient conditions :

Solid tumors

HITV is applicable for any type of solid cancers and any stage. However, it is not suitable for hematopoietic cancers such as leukemia.

Tumors are localized in treatable sites

As intra-tumoral injection of dendritic cells is the hallmark of HITV, it is important that the tumor is located in sites which are accessible by needle.

Tumor size of less than 3 cm in diameter

This limitation is due to the standard beam diameter of Tomotherapy which is 3 cm. Dendritic cell vaccine is also ineffective when injected into the necrotic center of large tumors.

Less than 5 metastatic tumor lesions

Again the limitation is due to the adverse reactions to radiotherapy that may occur when multiple sites have to be treated in one sitting. However Dr Hasumi has experience in treating up to 40 lesions in one go.

No pleural or ascitic effusion

Pleural and ascitic effusion are typical signs of extensive cancer dissemination and the chances of success in such cases is greatly diminished.

HITV Lab

HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks